Big Data’s Day Will Dawn Despite Big Questions, Experts Say
Executive Summary
The complexity of molecular datasets and issues around their use, like cost, are enormous challenges in oncology applications, but not insurmountable, leaders at the Cancer Progress conference say.
You may also be interested in...
With Perjeta, The Cost Of HER2 Breast Cancer Therapy Goes Up
Roche’s Perjeta will be priced at a premium to Herceptin and used in combination with it, more than doubling the cost of treating patients with HER2-positive metastatic breast cancer.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.